23.43

1.84% -0.44

After Hours: 22.60 -0.83 -3.54%

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $23.43, with a volume of 516.53K. It is down -1.84% in the last 24 hours and down -11.98% over the past month. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Previous Close:

$23.87

Open:

$23.84

24h Volume:

516.53K

Relative Volume:

0.43

Market Cap:

$2.95B

Revenue:

$236.00M

Net Income/Loss:

$-369.00M

P/E Ratio:

-7.3614

EPS:

-3.1828

Net Cash Flow:

$-489.00M

1W Performance:

-1.47%

1M Performance:

-11.98%

6M Performance:

+6.26%

1Y Performance:

+166.86%

1-Day Range:

$23.42

$24.34

1-Week Range:

$22.61

$24.41

52-Week Range:

$7.91

$28.72

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

601

Twitter

@arcusbio

Next Earnings Date

2026-05-05

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	23.43	3.00B	236.00M	-369.00M	-489.00M	-3.1828
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-13-26	Upgrade	Goldman	Neutral → Buy
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

May 23, 2026

Truist assumes Arcus Biosciences stock with buy on RCC potential By Investing.com - Investing.com Canada

May 18, 2026

May 17, 2026

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 21% - Sahm

May 17, 2026

May 16, 2026

Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts - Yahoo Finance

May 16, 2026

May 15, 2026

Why (RCUS) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 15, 2026

Top Arcus Biosciences (RCUS) Competitors 2026 - MarketBeat

May 15, 2026

May 14, 2026

What's going on with Arcus Biosciences stock on Wednesday? - MSN

May 14, 2026

May 12, 2026

Arcus Biosciences CFO Robert Goeltz sells $198,965 in stock By Investing.com - Investing.com Canada

May 12, 2026

Arcus Biosciences CFO Robert Goeltz sells $198,965 in stock - Investing.com

May 12, 2026

Arcus (NYSE: RCUS) director gifts 5,050 shares in estate move - Stock Titan

May 12, 2026

Arcus Biosciences (RCUS) CFO logs 7,763-share Rule 10b5-1 sale - Stock Titan

May 12, 2026

Arcus Biosciences stock (US75626R1077): Form 144 filing signals insider RSU sales - AD HOC NEWS

May 12, 2026

TradingKey - tradingkey.com

May 12, 2026

May 11, 2026

Arcus Biosciences (RCUS) Form 144: Brokered notice for RSU sales via Merrill Lynch - Stock Titan

May 11, 2026

RCUS Maintained by Morgan Stanley -- Price Target Raised to $22 - GuruFocus

May 11, 2026

Earnings call transcript: Arcus Biosciences misses Q1 2026 forecasts, stock dips - Investing.com Nigeria

May 11, 2026

Earnings call transcript: Arcus Biosciences misses Q1 2026 forecasts, stock dips By Investing.com - Investing.com South Africa

May 11, 2026

May 08, 2026

Arcus Biosciences Q1 Loss Of US$128 Million Reinforces Bearish Profitability Concerns - Sahm

May 08, 2026

Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report - Yahoo Finance

May 08, 2026

Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st

May 08, 2026

May 07, 2026

RCUS Maintained by Goldman Sachs -- Price Target Raised to $34 - GuruFocus

May 07, 2026